Related Experiment Video
Updated: May 23, 2026

Electrophoretic Delivery of γ-aminobutyric Acid (GABA) into Epileptic Focus Prevents Seizures in Mice
Published on: May 16, 2019
Perspectives on the development of antioxidant antiepileptogenic agents
1Department of Pharmaceutical Sciences, College of Pharmacy - Glendale, Midwestern University, AZ 85308, USA.
Abstract:
Epilepsy is a chronic disorder of abnormal electrical activity in the brain characterized by recurrent unprovoked seizures. Currently used pharmaceutical agents do not treat the underlying disease process, and a significant proportion of epileptic patients are refractory to current therapies. Therefore there is a strong need for additional therapeutic agents, especially those that address the underlying disease process of epileptogenesis. The redox potential of cells is maintained by an appropriate balance between pro- and anti-oxidative molecules; oxidative stress and increases in toxic reactive oxygen species occur when this balance shifts towards oxidation. Neural tissues are especially sensitive to oxygen levels, and oxidative stress is thought to be involved in epileptogenesis. Increases in reactive oxygen species occur in response to sustained neuronal electrical activity and seizures. Therefore antioxidants have been suggested as therapeutic design strategies for the treatment and modulation of epilepsy. This minireview focuses on several key antioxidants and agents involved in defending against oxidative stress that may be targets for new antiepileptogenic drug design, including directacting antioxidants, Nrf2-activating agents, and prolyl-4-hydroxylase inhibitors. A description of the necessary physicochemical properties and a summary of animal models that are thought to be useful for developing antiepileptogenic agents are presented.
Related Concept Videos
Antiepileptic Drugs: GABAergic Pathway Potentiators
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
Antiepileptic Drugs: Glutamate Antagonists
Antiepileptic Drugs: Potassium Channel Activators
Ezogabine has gained approval as an adjunctive treatment...
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
Epilepsy and Seizures: Overview
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Antiepileptic Drugs: Sodium Channel Blockers
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...

